- |||||||||| budesonide / Generic mfg.
Lymphocytic Colitis: A large case series in the United Kingdom (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1992;
Treatment with either budesonide or loperamide generally lead to better symptom control, indicating patients should be referred to gastroenterology upon diagnosis. Clinicians should judiciously prescribe the above medications with clear indication and avoid prescribing indefinitely.
- |||||||||| budesonide / Generic mfg.
Patients with inflammatory bowel disease who are intolerant to thiopurine treatment (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1823;
Conclusion Patients who stopped thiopurines due to side-effects did not in general differ in the use of other treatment for IBD the first five year after initiated thiopurine treatment, except for the use of budesonides and non-TNF inhibitor biologics which was more commonly used in patients who stopped thiopurines due to side-effects. Patients with UC who stopped treatment due to side-effects had higher faecal calprotectin levels at follow-up than patients who tolerated thiopurines.
- |||||||||| aspirin / Generic mfg., budesonide / Generic mfg.
The association of drugs and clinical relapse in patients with microscopic colitis. A retrospective observational study. (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1768;
Background Smoking, the use of non-steroidal anti-inflammatory drugs (NSAID) acetylsalicylic acid (ASA), proton pump inhibitors, serotonin reuptake inhibitors (SSRI) and statins has been associated with microscopic colitis (MC)...Risk factors influence on the odds of having a prescription of oral budesonide and the odds of having a second course of budesonide (clinical relapse) were studied retrospectively...Conclusion The risk of a clinical relapse are associated with the use of NSAIDs but not with the use of ASA, PPIs, SSRIs and statins. We suggest that patients with MC use NSAID with caution.
- |||||||||| budesonide / Generic mfg., loperamide / Generic mfg.
Journal: Diagnosis and Pharmacological Management of Microscopic Colitis in Geriatric Care. (Pubmed Central) - Jan 17, 2024
Consequently, other therapeutic options (e.g., bismuth subsalicylate, biologics, loperamide, bile acid sequestrants, and thiopurines) recommended by available guidelines may be prescribed. Herein, clinically meaningful data is provided based on the latest evidence that may aid in reaching a diagnosis and establishing rational therapy in geriatric care to control symptoms and enhance the quality of life for those affected.
- |||||||||| Filspari (sparsentan) / Travere Therap, CSL Behring
Journal: Nephrology: what's new in 2023 (Pubmed Central) - Jan 17, 2024
Sodium bicarbonate does not seem to protect renal function in renal transplant patients. SGLT2 inhibitors may have a beneficial effect in these patients in terms of nephroprotection.
- |||||||||| Tarpeyo (budesonide) / Calliditas, Stada
Journal: IgA nephropathy (Pubmed Central) - Jan 17, 2024
Nefecon (encapsulated budesonide) is the first specific drug licensed for treatment of high risk IgAN patients. A
- |||||||||| arsenic trioxide / Generic mfg., budesonide / Generic mfg.
Journal: A case report of acute promyelocytic leukemia with mycosis fungoides. (Pubmed Central) - Jan 9, 2024
All-trans-retinoicacid in the treatment of APL must be given attention mycosis fungoides. Early diagnosis can guide accurate treatment, which is of great help in alleviating the pain of patients and improving the cure rate.
- |||||||||| budesonide / Generic mfg.
Journal: Clinical cases of microscopic colitis: Diagnosis and treatment issues. Case report (Pubmed Central) - Jan 6, 2024
There are difficulties in diagnosing this disease due to the variability of histological signs, variability of morphological changes in the mucous membrane of the colon in different parts of the colon, and the combination in one patient of not only various forms of microscopic colitis, but also other intestinal diseases. The article describes the differential diagnosis, an example of its staging and successful treatment of various forms of microscopic colitis with budesonide (two clinical cases presented).
- |||||||||| prednisone / Generic mfg., budesonide / Generic mfg.
Steroid use in a high proportion of IBD patients (Poster exhibition) - Dec 25, 2023 - Abstract #ECCOIBD2024ECCO_IBD_1236;
Long-term CS use is still common in practice, which could result in avoidable side-effects. Measuring CS dependency or excess in routine clinical practice is feasible and could form part of on-going quality improvement programs.
- |||||||||| budesonide / Generic mfg., ursodeoxycholic acid / Generic mfg.
Journal: Bilosomes and Biloparticles for the Delivery of Lipophilic Drugs: A Preliminary Study. (Pubmed Central) - Dec 23, 2023
Both in gastric and intestinal fluid, budesonide was released from bilosystems more slowly than the reference solution, while biloparticles showed a significant improvement in the passage of budesonide into aqueous solution. Immunofluorescence experiments indicated that ursodeoxycholic acid bilosomes containing budesonide are effective in reducing the inflammatory response induced by glucose oxidase stimuli and counteract ox-inflammatory damage within intestinal cells.
- |||||||||| budesonide / Generic mfg.
A new therapeutic option: What do budesonide suppositories offer? (A12) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_1124;
Immunofluorescence experiments indicated that ursodeoxycholic acid bilosomes containing budesonide are effective in reducing the inflammatory response induced by glucose oxidase stimuli and counteract ox-inflammatory damage within intestinal cells. Sponsored by Dr Falk
- |||||||||| Entyvio (vedolizumab) / Takeda
Limited long-term efficacy of corticosteroids in microscopic colitis emphasizing the need for advanced therapies (Poster exhibition) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_1060;
More advanced therapies are being used, including anti-TNF agents (n=25), vedolizumab (n=9) and JAK inhibitors (n=8)...However, more than 50% of patients relapsed upon steroid tapering and/or withdrawal, resulting in a substantial need for advanced therapy in this patient population. The long-term efficacy and safety of these advanced IBD therapies in MC should therefore be further investigated.
- |||||||||| Entyvio (vedolizumab) / Takeda
Limited long-term efficacy of corticosteroids in microscopic colitis emphasizing the need for advanced therapies (Lijn - Hilton Antwerp Old Town) - Dec 19, 2023 - Abstract #BWG2024BWG_72;
More advanced therapies are being used, including anti-TNF agents (n=25), vedolizumab (n=9) and JAK inhibitors (n=8)...However, more than 50% of patients relapsed upon steroid tapering and/or withdrawal, resulting in a substantial need for advanced therapy in this patient population. The long-term efficacy and safety of these advanced IBD therapies in MC should therefore be further investigated.
- |||||||||| cyclophosphamide / Generic mfg.
Budesonide Use for Grade 2 Gastrointestinal Graft-Versus-Host Disease after Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis () - Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_1031;
The introduction of post-transplant cyclophosphamide (PTCy) has allowed the ability to reduce immunological complications and increase the pool of suitable donors, increasing access to many HLA-disparate patients in the HLA mismatched setting with acceptable graft-versus-host disease (GVHD) rates, and even challenged the conventional use of calcineurin and methotrexate based GVHD prophylaxis strategies in the HLA-identical donor setting for HCT. In patients who underwent HCT with PTCy based GVHD prophylaxis with isolated grade 2 GI GVHD budesonide monotherapy resulted in good responses without the addition of systemic therapy, sparing the majority of patients toxicities associated with systemic treatment.
- |||||||||| budesonide / Generic mfg.
Review, Journal: Systemic and targeted steroids for the treatment of IgA nephropathy. (Pubmed Central) - Dec 6, 2023
However, the limited number of treated patients and the relatively short follow-up suggest caution before considering budesonide superior to the current six-months steroid pulses scheme. Long-term data on the efficacy and safety of TRF budesonide are awaited, together with the design of trials with a head-to-head comparison with systemic steroids before considering TRF-budesonide as the standard of care treatment for IgAN nephropathy.
- |||||||||| budesonide / Generic mfg.
Review, Journal: Expanding options of supportive care in IgA nephropathy. (Pubmed Central) - Dec 6, 2023
Targeted-release formulation of budesonide should replace systemic corticosteroids in patients with higher proteinuria and active histological lesions...The exact place of monoclonal antibodies and complement inhibitors will need to be determined. This article reviews potential supportive therapies currently available for patients with IgAN.
- |||||||||| budesonide / Generic mfg.
Review, Journal: IgA nephropathy. (Pubmed Central) - Dec 5, 2023
For those at high risk of disease progression, the 2021 KDIGO Clinical Practice Guideline suggests considering a 6-month course of systemic corticosteroid therapy; however, the efficacy of systemic steroid treatment is under debate and serious adverse effects are common. Advances in understanding the pathophysiology of IgAN have led to clinical trials of novel targeted therapies with acceptable safety profiles, including SGLT2 inhibitors, endothelin receptor blockers, targeted-release budesonide, B cell proliferation and differentiation inhibitors, as well as blockade of complement components.
- |||||||||| budesonide / Generic mfg.
Review, Journal: Microscopic Colitis: A Review Article. (Pubmed Central) - Nov 30, 2023
The primary objective of this detailed review is to enhance knowledge and understanding of this condition among healthcare providers to guide them with detailed information regarding epidemiology, clinical presentation, diagnosis, and appropriate management. In the assessment of individuals presenting with persistent chronic diarrhea, it is essential for healthcare providers
- |||||||||| Review, Journal: A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP). (Pubmed Central) - Nov 13, 2023
Trial completion date: Nov 2023 --> Apr 2024 | Trial primary completion date: Oct 2023 --> Feb 2024 Novel drugs that may be considered for use in early nephritis include TRF-budesonide; B-cell inhibiting agents including belimumab, telitacicept, blisibimod, VIS649, and BION-1301; B-cell depleting agents such as rituximab, ofatumumab, and bortezomib; sparsentan; angiotensin converting enzyme inhibitors (ACE-Is); and complement pathway inhibitors including avacopan, iptacopan, and narsoplimab.
- |||||||||| A-LINK: UTILIZING A LEARNING HEALTH NETWORK MODEL FOR IMPROVING OUTCOMES IN AUTOIMMUNE HEPATITIS (Room 304/306) - Oct 11, 2023 - Abstract #AASLD2023AASLD_943;
In a prospective prevalence study, only 61% were in remission and 33% were in steroid-free remission at a median of 3.8 years after diagnosis. These findings highlight the ongoing need for better pharmacological therapy and application of guideline-based care and is foundational for future implementation trials to improve biochemical and steroid-free remission rates in AIH.
- |||||||||| Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma, Humira (adalimumab) / AbbVie
Clinical, Retrospective data, Review, Journal: A Systematic Review and Meta-analysis of Randomized Clinical Trials on the Prevention and Treatment of Pouchitis after Ileoanal Pouch Anastomosis. (Pubmed Central) - Oct 10, 2023
Probiotics are effective in preventing pouchitis after IPAA. Antibiotics, including ciprofloxacin and metronidazole, are likely effective in treating active pouchitis.
- |||||||||| budesonide / Generic mfg.
Journal: Self-Immolative Carbamate Linkers for CD19-Budesonide Antibody-Drug Conjugates. (Pubmed Central) - Oct 3, 2023
Addition of a poly(ethylene glycol) group improved linker hydrophilicity, thereby providing CD19-budesonide ADCs with suitable properties. ADC23 demonstrated targeted delivery of budesonide to CD19-expressing cells and inhibited B-cell activation in mice.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Complete remission after sequential Inotuzumab, Blinatumomab and chemotherapy with concurrent donor lymphocyte infusions in relapsed pre-B-ALL after allogeneic stem cell transplantation. (Hall F) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1098;
A cytoreductive therapy with Doxorubicin 45mg/m 2 , Vincristine 2mg and a second DLI-application (1.5x10 7 CD3+cells/kg) followed in month four...Temporary, a hepatic GvHD grade I was observed, which was treated with budesonide orally...In conclusion, our case demonstrates that co-administration of DLI, InO, Blina and chemotherapy is feasible without severe GvHD. Given these promising results, this
- |||||||||| Filspari (sparsentan) / Travere Therap, CSL Behring
Journal: Treatment of IgA nephropathy: a rapidly evolving field. (Pubmed Central) - Sep 29, 2023
While targeted release budesonide has garnered the most attention, anti-B cell strategies and selective complement inhibition will most likely prove their added value. We propose a comprehensive approach that tackles the different targets in the pathophysiology of IgA nephropathy according to their relevance in the individual patient.
- |||||||||| Tarpeyo (budesonide) / Calliditas, Stada
Journal: IgA nephropathy (Pubmed Central) - Sep 26, 2023
Nefecon (encapsulated budesonide) is the first specific drug licensed for treatment of high risk IgAN patients. A
- |||||||||| Filspari (sparsentan) / Travere Therap, CSL Behring
Journal: Diagnosis and Treatment of IgA Nephropathy-2023 (Pubmed Central) - Sep 24, 2023
New promising therapeutics are enteral Budesonide or the dual angiotensin-II-receptor- and endothelin-receptor-antagonist Sparsentan. Rapidly progressive IgAN should be treated with corticosteroids and cyclophosphamide like ANCA-associated vasculitis.
- |||||||||| budesonide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Acupuncture Therapy for COVID-Related Olfactory Loss (clinicaltrials.gov) - Sep 21, 2023
P=N/A, N=32, Completed,
Recruiting --> Completed Active, not recruiting --> Completed | N=100 --> 32 | Trial primary completion date: Aug 2023 --> Apr 2023
|
